Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Accountprinceon Dec 14, 2022 3:49pm
309 Views
Post# 35171682

Paradigm Capital

Paradigm CapitalParadigm Capital is a firm that Chris Seto used to work at.  I presume that's why they get appointed to do all of Spectral's share issuances.  Scott McAuley of Paradigm revalued Spectral today and dropped the share price by $0.30 per share today to $1.90 per share.  The reason?  He now places a value of ZERO on Dialco after the announcement of the iDialco deal.  That confirms my suspicions that there is something in the agreement that will eventually result in the residual value of 30% of Dialco being worthless.  Otherwise why would he give it a ZERO value?  So we've spent many millions of dollars bringing this to the point of full FDA and Health Canada approval for SAMI and DIMI (except home use in the US).  We've hired the best in the business to run Dialco and we have two huge SAMI orders.  And all down the drain because management was incapable of fulfilling the agreement they negotiated with Infomed.  Squandered a huge asset we had through their incompetence.

Time for all the incompetent management to be fired for cause.
<< Previous
Bullboard Posts
Next >>